International Journal of Cancer Therapy and Oncology最新文献

{"title":"Cloning and expression of the V-domain of the CD166 in prokaryotic host cell","authors":"Hassan Dana, Vahid Marmari, A. Mazraeh, A. Ghamari, M. Forghanifard","doi":"10.14319/IJCTO.51.10","DOIUrl":"https://doi.org/10.14319/IJCTO.51.10","url":null,"abstract":"Purpose: CD166/ALCAM (Activated leukocyte cell adhesion molecule) as an immunoglobulin is implicated in cell migration. It is also involved in tumorigenesis of CRC (colorectal cancer) and known as a cancer stem cell marker. CD166, as a membrane protein, potentially represents either diagnostic or therapeutic capacities for CRC. Methods: In this study, the sequence of V domain was optimized for expression in prokaryotic host using online tools and cloned into pET-28a plasmid. The recombinant pET28a was transformed into the E. coli BL21DE3 using heat shock method and expression of recombinant V domain was examined using SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel electrophoresis). Results: The results confirmed protein expression of recombinant 22.77 kDa V domains in bacterial expression system. Conclusion: V domain of the CD166 was expressed successfully in E. coli bacteria. This recombinant fragment can be introduced as a suitable diagnostic and therapeutic candidate for screening and cancer-therapy of CRC patients, respectively.","PeriodicalId":13931,"journal":{"name":"International Journal of Cancer Therapy and Oncology","volume":"19 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2017-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74220616","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The comparison between TP53 gene polymorphisms (c.[215G>C]) homozygotes and heterozygotes in Breast Cancer Patients: A clinicopathological analysis","authors":"J. Huszno, E. Grzybowska, M. N. Bochenek, Z. Kołosza, K. Tęcza, Jolanta Pamuła Piłat, M. Mazur, E. Nowara","doi":"10.14319/ijcto.51.6","DOIUrl":"https://doi.org/10.14319/ijcto.51.6","url":null,"abstract":"Purpose: TP53 is a tumor suppressor gene which participates in regulation of cell cycle check points, DNA repair, and apoptosis. The aim of this study was to compare TP53 germ line gene polymorphisms (c.[215G>C]) wild – type homozygotes GG with heterozygotes GC according to clinicopathological factors. Methods: We reviewed the medical records of 87 (22% TP53 gene homozygotes and 78% heterozygotes) breast cancer patients who were diagnosed and treated in COI in Gliwice. Polymorphism profile was assessed by RFLP-PCR technique. Results: The presence of lobular invasive carcinoma was observed insignificantly more often in homozygotes, especially in the group of patients at the age below 50 years (29% vs. 4%, p = 0.095). Patients being TP53 gene heterozygotes had larger tumor size (T > 2) than homozygotes (16% vs. 5%, p = 0.450). There was observed a tendency to the presence of lymph node metastases (53% vs. 34%, p = 0.182) and higher Ki67 (> 20%) (69% vs. 46%, p = 0.209) in TP53 gene homozygotes. HER2 overexpression was associated with TP53 heterozygotes, especially in the group of patients at the age above 50 years (33% vs. 8%, p = 0.144). A negative receptor status was reported more frequently in homozygotes (43% vs.21%, p = 0.340) in patients with age below 50 years. Similarly higher histological grade G3 was detected more often in homozygotes in patients at the age below 50 years (80% vs. 33%, p = 0.130). Conclusion: TP53 gene homozygotes and heterozygotes differ from each other in respect of clinicopathological factors such as: histological type, lymph node metastases, higher Ki67 (> 20%), histological grade G3, ER/PR status, tumor size (T > 2), HER2 overexpression, cancer in family history and diabetes. Patient’s age was associated with the pathological characteristics of tumor.","PeriodicalId":13931,"journal":{"name":"International Journal of Cancer Therapy and Oncology","volume":"66 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2017-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83323295","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is targeting glycolysis with 2-deoxyglucose a viable therapeutic approach to bladder cancer?","authors":"Vladimir A. Valera, M. Ferretti, D. Prabharasuth, M. Chaimowitz, M. Choudhury, J. Phillips, S. Konno","doi":"10.14319/IJCTO.55.1","DOIUrl":"https://doi.org/10.14319/IJCTO.55.1","url":null,"abstract":"Purpose: Although several therapeutic options for bladder cancer are available, the poor efficacy and palpable side effects are a major concern. Establishing a more effective intervention is urgently demanded. Glycolysis is considered a strategic target and has been often investigated in various cancers. Particularly, 2-deoxyglucose (2DG), a glycolysis inhibitor, has been intensely studied and shown to be encouraging and promising. Accordingly, we investigated how targeting glycolysis with 2DG would be effective on bladder cancer cells. Methods: Bladder cancer 5637 cells were employed and cell viability was determined by MTT assay.  To explore the anticancer mechanism of 2DG linked to glycolysis, two glycolytic parameters of hexokinase (HK) activity and ATP synthesis, metabolic signaling pathways, and induction of apoptosis were examined. Whether 2DG may potentiate several chemotherapeutic drugs being clinically used was also assessed for its possible chemosensitizing effect. Results: A dose-dependent study of 2DG showed a 23-80% reduction in cell viability.  HK activity and cellular ATP level were decreased by ~46% and ~56% with 2DG, respectively, indicating the glycolysis inhibition.  AMP-activated protein kinase was activated while protein kinase B was inactivated and also mammalian target of rapamycin was inhibited with 2DG.  These modulations would lead to the growth cessation and the cell viability reduction. In fact, the down-regulation of anti-apoptotic bcl-2 and the up-regulation of pro-apoptotic Bax in 2DG-treated cells indicated induction of apoptosis. Moreover, chemotherapeutic drugs with poor cytotoxic activity were selectively sensitized with 2DG, resulting in a significantly improved cell viability reduction. Conclusion: 2DG has anticancer activity on bladder cancer cells and its anticancer mechanism involves the glycolysis inhibition, the modulations of certain signaling pathways, and induction of apoptosis. Additionally, 2DG has a chemosensitizing effect when combined with drugs. Thus, targeting glycolysis with 2DG appears to be an alternative, viable therapeutic approach to bladder cancer.","PeriodicalId":13931,"journal":{"name":"International Journal of Cancer Therapy and Oncology","volume":"10 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2017-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77737959","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dose-to-medium vs. dose-to-water: Dosimetric evaluation of head and neck VMAT cases using Monaco treatment planning system","authors":"S. K. Gopal, P. Dash","doi":"10.14319/IJCTO.44.16","DOIUrl":"https://doi.org/10.14319/IJCTO.44.16","url":null,"abstract":"Purpose: In this paper, we evaluate the dosimetric differences between absorbed dose to water and absorbed dose to medium in Monte Carlo (MC)-based calculations used for radiation therapy treatment plans. Methods: Thirty-four treated Head and Neck simultaneously integrated boost cases were analyzed retrospectively. All of them were planned by Monaco treatment planning system (TPS), calculated and reviewed on absorbed dose to medium (D m ) calculations and treated in Elekta Versa HD LINAC. Absorbed dose to medium D m was converted to absorbed dose to water D w in Monaco treatment planning system using the procedure based on stopping power ratios and the Bragg-Gray cavity theory. Dosimetric parameters were then compared and analyzed with respect to absorbed dose to medium (D m ) calculations for multiple planning target volumes (PTVs) and critical organs such as brainstem, spinal cord, left and right lens, left and right parotids, larynx, left and right middle ear and lips. Results: It was found that mean and minimum D w (i.e. D w mean and D w min ) of organs at risk did not differ much (hardly differing by 0.8-2%) with respect to those of the absorbed dose to medium. However maximum D w (i.e. D w max ) in case of lips, left and right middle ear were found to differ more than 4% with respect to D m max . For serial organs brainstem and spinal cord, maximum dose D w max were found to vary around 1% and 2%, respectively, with respect to absorbed dose to medium dose calculation. In case of PTVs, the mean percentages variation of D w min and D w mean were found to be less than 1 %, although the variation of maximum D w was found to be high around 5-7% with respect to that of D m . Conclusion: The comparative analysis of dosimetric parameters in the present study shows that the selection of either D m or D w in Monaco planning system is less likely to produce any significant clinical effect in tumor control and to the damage of organs at risk.","PeriodicalId":13931,"journal":{"name":"International Journal of Cancer Therapy and Oncology","volume":"6 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2016-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73522948","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Low-dose versus high-dose radioactive iodine ablation of differentiated thyroid carcinoma: a prospective randomized study","authors":"D. Ibrahim, M. Kelaney, M. Michael, Z. El-Sayed","doi":"10.14319/IJCTO.44.15","DOIUrl":"https://doi.org/10.14319/IJCTO.44.15","url":null,"abstract":"Purpose: Following total thyroidectomy of differentiated thyroid carcinoma (DTC), some patients are ablated with radioactive iodine I-131 (RAI). We compare the success of ablation with 30 millicurie (mCi) versus 80 mCi. Methods: We randomized the patients to 30 mCi or 80 mCi RAI after surgery. T1-T3, N0-N1, M0 tumors were included (based on the AJCC 7th edition). Pre-ablation baseline serum thyroglobulin (sTg), and thyroglobulin antibody (Tg Ab) were performed. Six months post-ablation successful thyroid ablation was defined as a negative whole body scan (WBS) and undetectable sTg. Results: Out of 50 patients with DTC, 45 patients fulfilled the eligibility criteria. Total thyroidectomy was performed in 27/ 45 (60%). 26/45 (57.8%) of patients received 30 mCi while 19/45 (42.2%) patients received 80 mCi. The median age was 37 and 36.5 years in the arms 80 and 30 mCi respectively. Papillary carcinoma predominated in 42/45 (93.3%) of patients. T2 tumors predominated in 10/19 (52.6%), and 15/26 (57.7%) of the 80 and 30 mCi arms respectively. According to the American Thyroid Association (ATA) risk classification, all of the patients had low risk disease. Success of ablation was achieved in 15/19 (78.9%), and in 15/26 (57. 7%) of the arms 80 and 30 mCi respectively. No patients developed distant metastases in both arms. The patients who received 80 mCi had longer hospital isolation than the 30 mCi arm (p 0.008). 6/26 (23.1%) patients in the 30 mCi arm were isolated for 2-4 days, whereas all the 80 mCi arm patients were isolated for 3-5 days. Conclusion: Both 80 mCi and 30 mCi RAI have similar success rate in the ablation of thyroid remnant of low risk DTC patients. The low dose is associated with fewer side effects, shorter hospital admission duration, and is less expensive in low risk DTC patients.","PeriodicalId":13931,"journal":{"name":"International Journal of Cancer Therapy and Oncology","volume":"25 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2016-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82762135","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Guanylyl Cyclase C as a tumor marker for detection of circulating tumor cells in the peripheral blood of colorectal cancer patients","authors":"M. Moghbeli, Somaye Chavoshi, M. Tavallaie, E. Dadkhah, Reza Raeissosadati, M. Farshchian, Mohsen Towliat Kashani, A. Ganji, A. Jangjoo, Samaneh Bromand Noughabi, M. Abbaszadegan","doi":"10.14319/IJCTO.44.11","DOIUrl":"https://doi.org/10.14319/IJCTO.44.11","url":null,"abstract":"Purpose: Guanylyl cyclase C (GCC) is one of the most frequent tumor markers to detect the circulating tumor cells (CTCs) in peripheral blood of colorectal cancer (CRC) patients. It has been proposed as a new marker for the molecular staging of CRC. The level of GCC mRNA expression in peripheral blood of CRC patients was evaluated to explore its probable correlations with the clinicopathological features. Methods: Relative quantitative expression analysis of GCC mRNA was performed on 80 blood samples (40 patients and 40 normal) using the Real-time RT-PCR. Results: GCC mRNA expression was detected in 70% of the CRC blood samples. The level of GCC mRNA expression in peripheral blood of patients was significantly higher than that in the normal cases (p = 0.031). Moreover, there was a significant correlation between the GCC copy number and advanced stages of tumor (p = 0.041). Furthermore, we have observed a significant correlation between tumor sizes and GCC copy numbers (p = 0.050). Conclusion: GCC can be a useful marker not only for detection of CTCs in CRC blood samples, but also for the molecular staging of colorectal cancer.","PeriodicalId":13931,"journal":{"name":"International Journal of Cancer Therapy and Oncology","volume":"6 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2016-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88937437","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of preoperative 18-FDG- PET/CT in early-stage breast cancer upstaging and modification of treatment","authors":"A. Tewari, S. Sundaram, P. Subramanyam","doi":"10.14319/IJCTO.44.13","DOIUrl":"https://doi.org/10.14319/IJCTO.44.13","url":null,"abstract":"Purpose: The aim of this study was to assess the diagnostic and therapeutic impact of preoperative positron emission tomography and computed tomography (PET/CT) in the initial staging of patients with early-stage breast cancer. Methods: A total of 72 consecutive patients (age: range 24-78 years, mean 51 years), with newly diagnosed operable breast cancer (Infiltrating Ductal carcinoma: Lobular carcinoma: Others - 49:15:8) with tumor size 10-65 mm were examined preoperatively. All patients underwent conventional assessment imaging modalities like mammography, breast/axillary ultrasound and PET/CT. Results:  PET/CT identified a primary tumor in all but two patients. PET/CT solely detected unsuspected distant metastases (bones, lung, brain etc) in 9 patients and new primary cancers (endometrium and lung) in another two patients, as well as 11 cases of extra-axillary lymph node involvement. In 6 patients, extra-axillary malignancy was detected by PET/CT only, leading to an upgrade of initial staging in 9% (6/70) and ultimately a modification of planned treatment in 12% (9/70) of patients. PET/CT evaluation led 5 patients of stage II A to stage IV, 3 patients of stage II B to stage IV and 1 patient to Stage IIIB which further modified treatment plan from an adjuvant to a metastatic approach. Conclusion: PET/CT is a valuable tool to provide information on extra-axillary lymph node involvement, distant metastases and other occult primary cancers. Preoperative 18 F fluorodeoxyglucose PET/CT has a substantial impact on initial staging and on clinical management in patients with early-stage breast cancer.","PeriodicalId":13931,"journal":{"name":"International Journal of Cancer Therapy and Oncology","volume":"10 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2016-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91283042","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long term survival after brain metastases from malignant melanoma","authors":"C. Salvador-Coloma, J. Montalar, O. M. Niño, A. Tormo, J. Aparicio","doi":"10.14319/IJCTO.44.8","DOIUrl":"https://doi.org/10.14319/IJCTO.44.8","url":null,"abstract":"We present the case of a 32-year-old patient with malignant melanoma who relapsed with an unresectable brain metastases (BM). He was managed with whole brain radiotherapy (WBRT) and temozolomide chemotherapy. A metabolic positron emission tomography (PET-scan) complete response was achieved. He is living disease-free more than 6 years after the diagnosis of BM. He is now 51 years old and remains asymptomatic and free of disease since then. However, a pronounced residual image still appears on magnetic resonance imaging (MRI) ant PET-scan.","PeriodicalId":13931,"journal":{"name":"International Journal of Cancer Therapy and Oncology","volume":"449 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2016-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82908625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"What should we know about photon dose calculation algorithms used for radiotherapy? Their impact on dose distribution and medical decisions based on TCP/NTCP","authors":"A. Chaikh, T. Kumar, J. Balosso","doi":"10.14319/IJCTO.44.18","DOIUrl":"https://doi.org/10.14319/IJCTO.44.18","url":null,"abstract":"The dose calculation algorithms, integrated in a radiotherapy treatment planning system, use different approximations to swiftly compute the dose distributions. Any biological effect is somehow related to the dose delivered to the tissues. Thus, the optimization of treatment planning in radiation oncology requires, as a basis, the most accurate dose calculation to carry out the best possible prediction of the Normal Tissue Complication Probability (NTCP), as well as Tumor Control Probability (TCP). Presently, a number of bio-mathematical models exist to estimate TCP and NTCP from a physical calculated dose using the differential dose volume histogram (dDVH). The purpose of this review is to highlight the link between any change of algorithms and possible significant changes of DVH metrics, TCP, NTCP and even more of estimated Quality-adjusted life years (QALY) based on predicted NTCP. The former algorithms, such as pencil beam convolution (PBC) algorithm with 1D or 3D density correction methods, overestimated the TCP while underestimating NTCP for lung cancer. The magnitude of error depends on the algorithms, the radiobiological models and their assumed radiobiological parameters setting. The over/under estimation of radiotherapy outcomes can reach up to 50% relatively. Presently, the anisotropic analytical algorithm (AAA), collapsed cone convolution algorithm (CCC), Acuros-XB or Monte Carlo are the most recommended algorithms to consistently estimate the TCP/ NTCP outcomes and QALY score, to rank and compare radiotherapy plans, to make a useful medical decision regarding the best plan. This paper points out also that the values of the NTCP radiobiological parameters should be adjusted to each dose calculation algorithm to provide the most accurate estimates.","PeriodicalId":13931,"journal":{"name":"International Journal of Cancer Therapy and Oncology","volume":"40 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2016-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78803500","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Estimation of linear quadratic (LQ) model parameter alpha/beta (α/β) and biologically effective dose (BED) for acute normal tissue reactions in head and neck malignancies","authors":"Mirza Athar Ali, S. Jakhar, D. Punia, M. Bardia, Ajay Sharma, H. Kumar, Sandeep Jain, N. Sharma, Vinod Agrawal, K. Harsh, A. Kalwar, M. Babaiah, Prabhakar Mariappan, N. Madhusudhan, Sujana Priya Vuba","doi":"10.14319/IJCTO.44.9","DOIUrl":"https://doi.org/10.14319/IJCTO.44.9","url":null,"abstract":"Purpose: Linear-Quadratic (LQ) model has been widely used for describing radiobiological effectiveness of various fractionation schedules on tumour as well as normal tissues. This study estimates α/β for acute normal tissue reactions using Fe-plot method. Methods: 50 cases of locally advanced head and neck squamous cell carcinoma (stage III and IV) treated with external beam radiotherapy were included in this study. Patients were randomly distributed into Hyper-fractionation (HF) arm (1.2 Gy/fraction, twice daily, 6 hours apart) and conventional fractionation (CF) arm (2 Gy/fraction, once daily) with 25 cases in each arm. α/β and BED were calculated for acute normal tissue reactions using Fe-plot method. Results: In our study, the estimated values of α/β for RTOG (Radiation Therapy Oncology Group) grade 1, 2 and 3 skin reactions were 11.2 Gy, 10.1 Gy and 9 Gy respectively. Estimated values of α/β for RTOG grade 1, 2 and 3 mucosal reactions were 9.7 Gy, 8.0 Gy and 9.1 Gy respectively. For Hyper-fractionation arm, calculated BED values for grade 1, 2 and 3 skin reactions were 54.45 Gy 11.239 , 66.90 Gy 10.114 and 73.43Gy 9.001 respectively and for grade 1, 2 and 3 mucosal reactions were 33.5 Gy 9.797 , 57.8 Gy 8.011 and 70.8 Gy 9.106 respectively. For conventional fractionation arm, calculated BED values for grade 1, 2 and 3 skin reactions were 54.09 Gy 11.239 , 66.88 Gy 10.114 and 73.33 Gy 9.001 respectively and for grade 1, 2 and 3 mucosal reactions were 33.52 Gy 9.797 , 57.68 Gy 8.011 and 70.73 Gy 9.106 respectively. Conclusion: LQ model and the concept of BED provide an excellent tool to compare different fractionation schedules in radiotherapy. The estimated values of α/β for acute reacting normal tissues are in good agreement with the available literature.","PeriodicalId":13931,"journal":{"name":"International Journal of Cancer Therapy and Oncology","volume":"8 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2016-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75287547","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}